Governing the AI-biotech convergence : The rapid progress in and the dual-use nature of biotechnology and AI requires adaptive and resilient regulatory frameworks to address potential risks.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Enhanced classification and identification of bacterial and viral microorganisms by integration of MALDI-TOF mass spectrometry with artificial intelligence.Scientific reports · 2026
   Article
2. The time window before biological AI spreads : To prevent the misuse of biological AI models with dual-use capabilities requires governance of the embargo window.EMBO reports · 2026
   Article
3. Governing synthetic biology and artificial intelligence (AI) convergence: emerging biosecurity priorities for Africa.Frontiers in bioengineering and biotechnology · 2026
   Review
4. Improving governance in the age of synthetic biology, artificial intelligence, and diverging threats.Frontiers in bioengineering and biotechnology · 2026
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

17 authors.

Funding

Abstract

PubMed holds no abstract for this paper.